詳細検索

詳細検索

お問い合わせ

Global Biopharmaceutical Contract Manufacturing (BCMO) Market Outlook, InDepth Analysis & Forecast to 2032

Global Biopharmaceutical Contract Manufacturing (BCMO) Market Outlook, InDepth Analysis & Forecast to 2032


バイオ医薬品受託製造(BCMO)の世界市場 2026-2032年

The global Biopharmaceutical Contract Manufacturing (BCMO) market is projected to grow from US$ 89453 million in 2025 to US$ 173452 million by 2032, at a CAGR of 9.9% (2026-2032), driven by critica... もっと見る

 

 

出版社
QYResearch
QYリサーチ
出版年月
2026年11月15日
電子版価格
US$4,900
シングルユーザライセンス
ライセンス・価格情報/注文方法はこちら
納期
5-7営業日
言語
英語

英語原文をAIを使って翻訳しています。


 

お問い合わせ

お問合せ種類/内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る



図表リスト

List of Tables
Table 1. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Manufacturing Service Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Region (US$ Million), 2021-2026
Table 7. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Players (US$ Million), 2021-2026
Table 10. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Biopharmaceutical Contract Manufacturing (BCMO) Revenue, 2025
Table 13. Global Biopharmaceutical Contract Manufacturing (BCMO) Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Biopharmaceutical Contract Manufacturing (BCMO) Companies Headquarters
Table 15. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Type (US$ Million), 2021-2026
Table 19. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Type (US$ Million), 2027-2032
Table 20. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Manufacturing Service Type (US$ Million), 2021-2026
Table 21. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Manufacturing Service Type (US$ Million), 2027-2032
Table 22. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Development and Commercialization Stage (US$ Million), 2021-2026
Table 23. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Development and Commercialization Stage (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Application (US$ Million), 2021-2026
Table 26. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Application (US$ Million), 2027-2032
Table 27. Biopharmaceutical Contract Manufacturing (BCMO) High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Biopharmaceutical Contract Manufacturing (BCMO) Growth Accelerators and Market Barriers
Table 31. North America Biopharmaceutical Contract Manufacturing (BCMO) Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Biopharmaceutical Contract Manufacturing (BCMO) Growth Accelerators and Market Barriers
Table 33. Europe Biopharmaceutical Contract Manufacturing (BCMO) Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Biopharmaceutical Contract Manufacturing (BCMO) Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Biopharmaceutical Contract Manufacturing (BCMO) Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Biopharmaceutical Contract Manufacturing (BCMO) Investment Opportunities and Key Challenges
Table 37. Central and South America Biopharmaceutical Contract Manufacturing (BCMO) Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Biopharmaceutical Contract Manufacturing (BCMO) Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Biopharmaceutical Contract Manufacturing (BCMO) Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Lonza Group AG Corporation Information
Table 41. Lonza Group AG Description and Major Businesses
Table 42. Lonza Group AG Product Features and Attributes
Table 43. Lonza Group AG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Lonza Group AG Revenue Proportion by Product in 2025
Table 45. Lonza Group AG Revenue Proportion by Application in 2025
Table 46. Lonza Group AG Revenue Proportion by Geographic Area in 2025
Table 47. Lonza Group AG Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
Table 48. Lonza Group AG Recent Developments
Table 49. Samsung Biologics Co., Ltd. Corporation Information
Table 50. Samsung Biologics Co., Ltd. Description and Major Businesses
Table 51. Samsung Biologics Co., Ltd. Product Features and Attributes
Table 52. Samsung Biologics Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Samsung Biologics Co., Ltd. Revenue Proportion by Product in 2025
Table 54. Samsung Biologics Co., Ltd. Revenue Proportion by Application in 2025
Table 55. Samsung Biologics Co., Ltd. Revenue Proportion by Geographic Area in 2025
Table 56. Samsung Biologics Co., Ltd. Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
Table 57. Samsung Biologics Co., Ltd. Recent Developments
Table 58. WuXi Biologics (Cayman) Inc. Corporation Information
Table 59. WuXi Biologics (Cayman) Inc. Description and Major Businesses
Table 60. WuXi Biologics (Cayman) Inc. Product Features and Attributes
Table 61. WuXi Biologics (Cayman) Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. WuXi Biologics (Cayman) Inc. Revenue Proportion by Product in 2025
Table 63. WuXi Biologics (Cayman) Inc. Revenue Proportion by Application in 2025
Table 64. WuXi Biologics (Cayman) Inc. Revenue Proportion by Geographic Area in 2025
Table 65. WuXi Biologics (Cayman) Inc. Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
Table 66. WuXi Biologics (Cayman) Inc. Recent Developments
Table 67. FUJIFILM Holdings Corporation Corporation Information
Table 68. FUJIFILM Holdings Corporation Description and Major Businesses
Table 69. FUJIFILM Holdings Corporation Product Features and Attributes
Table 70. FUJIFILM Holdings Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. FUJIFILM Holdings Corporation Revenue Proportion by Product in 2025
Table 72. FUJIFILM Holdings Corporation Revenue Proportion by Application in 2025
Table 73. FUJIFILM Holdings Corporation Revenue Proportion by Geographic Area in 2025
Table 74. FUJIFILM Holdings Corporation Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
Table 75. FUJIFILM Holdings Corporation Recent Developments
Table 76. AGC Inc. Corporation Information
Table 77. AGC Inc. Description and Major Businesses
Table 78. AGC Inc. Product Features and Attributes
Table 79. AGC Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. AGC Inc. Revenue Proportion by Product in 2025
Table 81. AGC Inc. Revenue Proportion by Application in 2025
Table 82. AGC Inc. Revenue Proportion by Geographic Area in 2025
Table 83. AGC Inc. Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
Table 84. AGC Inc. Recent Developments
Table 85. Boehringer Ingelheim International GmbH Corporation Information
Table 86. Boehringer Ingelheim International GmbH Description and Major Businesses
Table 87. Boehringer Ingelheim International GmbH Product Features and Attributes
Table 88. Boehringer Ingelheim International GmbH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Boehringer Ingelheim International GmbH Recent Developments
Table 90. Thermo Fisher Scientific Inc. Corporation Information
Table 91. Thermo Fisher Scientific Inc. Description and Major Businesses
Table 92. Thermo Fisher Scientific Inc. Product Features and Attributes
Table 93. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Thermo Fisher Scientific Inc. Recent Developments
Table 95. Novo Holdings A/S Corporation Information
Table 96. Novo Holdings A/S Description and Major Businesses
Table 97. Novo Holdings A/S Product Features and Attributes
Table 98. Novo Holdings A/S Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Novo Holdings A/S Recent Developments
Table 100. Rentschler Biopharma SE Corporation Information
Table 101. Rentschler Biopharma SE Description and Major Businesses
Table 102. Rentschler Biopharma SE Product Features and Attributes
Table 103. Rentschler Biopharma SE Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Rentschler Biopharma SE Recent Developments
Table 105. KBI Biopharma, Inc. Corporation Information
Table 106. KBI Biopharma, Inc. Description and Major Businesses
Table 107. KBI Biopharma, Inc. Product Features and Attributes
Table 108. KBI Biopharma, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. KBI Biopharma, Inc. Recent Developments
Table 110. Ajinomoto Co., Inc. Corporation Information
Table 111. Ajinomoto Co., Inc. Description and Major Businesses
Table 112. Ajinomoto Co., Inc. Product Features and Attributes
Table 113. Ajinomoto Co., Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Ajinomoto Co., Inc. Recent Developments
Table 115. LOTTE BIOLOGICS Corporation Information
Table 116. LOTTE BIOLOGICS Description and Major Businesses
Table 117. LOTTE BIOLOGICS Product Features and Attributes
Table 118. LOTTE BIOLOGICS Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. LOTTE BIOLOGICS Recent Developments
Table 120. Polpharma Biologics Corporation Information
Table 121. Polpharma Biologics Description and Major Businesses
Table 122. Polpharma Biologics Product Features and Attributes
Table 123. Polpharma Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Polpharma Biologics Recent Developments
Table 125. EirGenix, Inc. Corporation Information
Table 126. EirGenix, Inc. Description and Major Businesses
Table 127. EirGenix, Inc. Product Features and Attributes
Table 128. EirGenix, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. EirGenix, Inc. Recent Developments
Table 130. Richter-Helm BioLogics GmbH & Co. KG Corporation Information
Table 131. Richter-Helm BioLogics GmbH & Co. KG Description and Major Businesses
Table 132. Richter-Helm BioLogics GmbH & Co. KG Product Features and Attributes
Table 133. Richter-Helm BioLogics GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Richter-Helm BioLogics GmbH & Co. KG Recent Developments
Table 135. Simtra BioPharma Solutions Corporation Information
Table 136. Simtra BioPharma Solutions Description and Major Businesses
Table 137. Simtra BioPharma Solutions Product Features and Attributes
Table 138. Simtra BioPharma Solutions Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Simtra BioPharma Solutions Recent Developments
Table 140. Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information
Table 141. Vetter Pharma-Fertigung GmbH & Co. KG Description and Major Businesses
Table 142. Vetter Pharma-Fertigung GmbH & Co. KG Product Features and Attributes
Table 143. Vetter Pharma-Fertigung GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments
Table 145. Piramal Pharma Limited Corporation Information
Table 146. Piramal Pharma Limited Description and Major Businesses
Table 147. Piramal Pharma Limited Product Features and Attributes
Table 148. Piramal Pharma Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Piramal Pharma Limited Recent Developments
Table 150. AbbVie Inc. Corporation Information
Table 151. AbbVie Inc. Description and Major Businesses
Table 152. AbbVie Inc. Product Features and Attributes
Table 153. AbbVie Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. AbbVie Inc. Recent Developments
Table 155. Emergent BioSolutions Inc. Corporation Information
Table 156. Emergent BioSolutions Inc. Description and Major Businesses
Table 157. Emergent BioSolutions Inc. Product Features and Attributes
Table 158. Emergent BioSolutions Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Emergent BioSolutions Inc. Recent Developments
Table 160. SK pharmteco Corporation Information
Table 161. SK pharmteco Description and Major Businesses
Table 162. SK pharmteco Product Features and Attributes
Table 163. SK pharmteco Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. SK pharmteco Recent Developments
Table 165. Oxford Biomedica plc Corporation Information
Table 166. Oxford Biomedica plc Description and Major Businesses
Table 167. Oxford Biomedica plc Product Features and Attributes
Table 168. Oxford Biomedica plc Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. Oxford Biomedica plc Recent Developments
Table 170. WuXi XDC Cayman Inc. Corporation Information
Table 171. WuXi XDC Cayman Inc. Description and Major Businesses
Table 172. WuXi XDC Cayman Inc. Product Features and Attributes
Table 173. WuXi XDC Cayman Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. WuXi XDC Cayman Inc. Recent Developments
Table 175. Porton Pharma Solutions Ltd. Corporation Information
Table 176. Porton Pharma Solutions Ltd. Description and Major Businesses
Table 177. Porton Pharma Solutions Ltd. Product Features and Attributes
Table 178. Porton Pharma Solutions Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Porton Pharma Solutions Ltd. Recent Developments
Table 180. Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information
Table 181. Asymchem Laboratories (Tianjin) Co., Ltd. Description and Major Businesses
Table 182. Asymchem Laboratories (Tianjin) Co., Ltd. Product Features and Attributes
Table 183. Asymchem Laboratories (Tianjin) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments
Table 185. BioVectra Inc. Corporation Information
Table 186. BioVectra Inc. Description and Major Businesses
Table 187. BioVectra Inc. Product Features and Attributes
Table 188. BioVectra Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. BioVectra Inc. Recent Developments
Table 190. Bora Pharmaceuticals Co., Ltd. Corporation Information
Table 191. Bora Pharmaceuticals Co., Ltd. Description and Major Businesses
Table 192. Bora Pharmaceuticals Co., Ltd. Product Features and Attributes
Table 193. Bora Pharmaceuticals Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Bora Pharmaceuticals Co., Ltd. Recent Developments
Table 195. Recipharm AB Corporation Information
Table 196. Recipharm AB Description and Major Businesses
Table 197. Recipharm AB Product Features and Attributes
Table 198. Recipharm AB Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. Recipharm AB Recent Developments
Table 200. Minaris Regenerative Medicine Corporation Information
Table 201. Minaris Regenerative Medicine Description and Major Businesses
Table 202. Minaris Regenerative Medicine Product Features and Attributes
Table 203. Minaris Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. Minaris Regenerative Medicine Recent Developments
Table 205. Cellipont Bioservices Corporation Information
Table 206. Cellipont Bioservices Description and Major Businesses
Table 207. Cellipont Bioservices Product Features and Attributes
Table 208. Cellipont Bioservices Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. Cellipont Bioservices Recent Developments
Table 210. Andelyn Biosciences Corporation Information
Table 211. Andelyn Biosciences Description and Major Businesses
Table 212. Andelyn Biosciences Product Features and Attributes
Table 213. Andelyn Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 214. Andelyn Biosciences Recent Developments
Table 215. Danaher Corporation Corporation Information
Table 216. Danaher Corporation Description and Major Businesses
Table 217. Danaher Corporation Product Features and Attributes
Table 218. Danaher Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 219. Danaher Corporation Recent Developments
Table 220. BioCina Corporation Information
Table 221. BioCina Description and Major Businesses
Table 222. BioCina Product Features and Attributes
Table 223. BioCina Revenue (US$ Million) and Gross Margin (2021-2026)
Table 224. BioCina Recent Developments
Table 225. Syngene International Limited Corporation Information
Table 226. Syngene International Limited Description and Major Businesses
Table 227. Syngene International Limited Product Features and Attributes
Table 228. Syngene International Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 229. Syngene International Limited Recent Developments
Table 230. Aragen Life Sciences Corporation Information
Table 231. Aragen Life Sciences Description and Major Businesses
Table 232. Aragen Life Sciences Product Features and Attributes
Table 233. Aragen Life Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 234. Aragen Life Sciences Recent Developments
Table 235. MabPlex International Corporation Information
Table 236. MabPlex International Description and Major Businesses
Table 237. MabPlex International Product Features and Attributes
Table 238. MabPlex International Revenue (US$ Million) and Gross Margin (2021-2026)
Table 239. MabPlex International Recent Developments
Table 240. GenScript Biotech Corporation Corporation Information
Table 241. GenScript Biotech Corporation Description and Major Businesses
Table 242. GenScript Biotech Corporation Product Features and Attributes
Table 243. GenScript Biotech Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 244. GenScript Biotech Corporation Recent Developments
Table 245. Chime Biologics Corporation Information
Table 246. Chime Biologics Description and Major Businesses
Table 247. Chime Biologics Product Features and Attributes
Table 248. Chime Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 249. Chime Biologics Recent Developments
Table 250. Hangzhou HJB Corporation Information
Table 251. Hangzhou HJB Description and Major Businesses
Table 252. Hangzhou HJB Product Features and Attributes
Table 253. Hangzhou HJB Revenue (US$ Million) and Gross Margin (2021-2026)
Table 254. Hangzhou HJB Recent Developments
Table 255. BiBo Pharma Corporation Information
Table 256. BiBo Pharma Description and Major Businesses
Table 257. BiBo Pharma Product Features and Attributes
Table 258. BiBo Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 259. BiBo Pharma Recent Developments
Table 260. Technologies, Platforms and Infrastructure
Table 261. Distributors List
Table 262. Market Trends and Market Evolution
Table 263. Market Drivers and Opportunities
Table 264. Market Challenges, Risks, and Restraints
Table 265. Research Programs/Design for This Report
Table 266. Key Data Information from Secondary Sources
Table 267. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Monoclonal and Multispecific Antibodies Product Picture
Figure 3. Antibody-Drug Conjugates (ADCs) Product Picture
Figure 4. Vaccines Product Picture
Figure 5. Cell Therapy Products Product Picture
Figure 6. Gene Therapy and Viral Vector Products Product Picture
Figure 7. Nucleic Acid Therapeutics Product Picture
Figure 8. Others Product Picture
Figure 9. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Manufacturing Service Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 10. Drug Substance Manufacturing Product Picture
Figure 11. Drug Product Manufacturing Product Picture
Figure 12. Integrated Drug Substance and Drug Product Manufacturing Product Picture
Figure 13. Others Product Picture
Figure 14. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Preclinical and IND-enabling Manufacturing Product Picture
Figure 16. Phase I Clinical Manufacturing Product Picture
Figure 17. Phase II Clinical Manufacturing Product Picture
Figure 18. Phase III Clinical Manufacturing Product Picture
Figure 19. Others Product Picture
Figure 20. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 21. Bio-Pharmaceutical Companies
Figure 22. Pharmaceutical Companies
Figure 23. Drug Discovery Companies
Figure 24. Others
Figure 25. Biopharmaceutical Contract Manufacturing (BCMO) Report Years Considered
Figure 26. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 27. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 28. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 29. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue-Based Market Share by Region (2021-2032)
Figure 30. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue-Based Market Share Ranking (2025)
Figure 31. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 32. Monoclonal and Multispecific Antibodies Revenue-Based Market Share by Player in 2025
Figure 33. Antibody-Drug Conjugates (ADCs) Revenue-Based Market Share by Player in 2025
Figure 34. Vaccines Revenue-Based Market Share by Player in 2025
Figure 35. Cell Therapy Products Revenue-Based Market Share by Player in 2025
Figure 36. Gene Therapy and Viral Vector Products Revenue-Based Market Share by Player in 2025
Figure 37. Nucleic Acid Therapeutics Revenue-Based Market Share by Player in 2025
Figure 38. Others Revenue-Based Market Share by Player in 2025
Figure 39. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue-Based Market Share by Type (2021-2032)
Figure 40. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue-Based Market Share by Manufacturing Service Type (2021-2032)
Figure 41. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue-Based Market Share by Development and Commercialization Stage (2021-2032)
Figure 42. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue-Based Market Share by Application (2021-2032)
Figure 43. North America Biopharmaceutical Contract Manufacturing (BCMO) Revenue YoY (US$ Million), 2021-2032
Figure 44. North America Top 5 Players Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) in 2025
Figure 45. North America Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) by Application (2021-2032)
Figure 46. US Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 47. Canada Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 48. Mexico Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 49. Europe Biopharmaceutical Contract Manufacturing (BCMO) Revenue YoY (US$ Million), 2021-2032
Figure 50. Europe Top 5 Players Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) in 2025
Figure 51. Europe Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) by Application (2021-2032)
Figure 52. Germany Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 53. France Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 54. U.K. Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 55. Italy Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 56. Russia Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 57. Asia-Pacific Biopharmaceutical Contract Manufacturing (BCMO) Revenue YoY (US$ Million), 2021-2032
Figure 58. Asia-Pacific Top 8 Players Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) in 2025
Figure 59. Asia-Pacific Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) by Application (2021-2032)
Figure 60. Indonesia Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 61. Japan Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 62. South Korea Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 63. Australia Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 64. India Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 65. Indonesia Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 66. Vietnam Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 67. Malaysia Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 68. Philippines Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 69. Singapore Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 70. Central and South America Biopharmaceutical Contract Manufacturing (BCMO) Revenue YoY (US$ Million), 2021-2032
Figure 71. Central and South America Top 5 Players Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) in 2025
Figure 72. Central and South America Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) by Application (2021-2032)
Figure 73. Brazil Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 74. Argentina Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 75. Middle East and Africa Biopharmaceutical Contract Manufacturing (BCMO) Revenue YoY (US$ Million), 2021-2032
Figure 76. Middle East and Africa Top 5 Players Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) in 2025
Figure 77. Middle East and Africa Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) by Application (2021-2032)
Figure 78. GCC Countries Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 79. Israel Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 80. Egypt Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 81. South Africa Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 82. Biopharmaceutical Contract Manufacturing (BCMO) Value Chain Mapping
Figure 83. Channels of Distribution (Direct Vs Distribution)
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed

 

ページTOPに戻る


 

Summary

The global Biopharmaceutical Contract Manufacturing (BCMO) market is projected to grow from US$ 89453 million in 2025 to US$ 173452 million by 2032, at a CAGR of 9.9% (2026-2032), driven by critical product segments and diverse end‑use applications.

Biopharmaceutical Contract Manufacturing (BCMO) refers to specialized outsourced manufacturing services provided by contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) for the production of biological pharmaceutical products. These services support biotechnology companies, pharmaceutical manufacturers, and emerging biopharmaceutical developers throughout clinical development, regulatory approval, and commercial production. The market primarily covers contract manufacturing of monoclonal antibodies, recombinant proteins, therapeutic enzymes, vaccines, antibody-drug conjugates (ADCs), and cell and gene therapies. Core manufacturing activities involve mammalian and microbial cell culture, upstream bioprocessing, downstream purification, aseptic fill-finish, formulation, analytical testing, quality control, and process validation. Depending on contractual arrangements, service providers may also undertake cell line development, process optimization, technology transfer, scale-up, and regulatory manufacturing support as integrated components of manufacturing projects. Biopharmaceutical Contract Manufacturing (BCMO) operates under stringent Good Manufacturing Practice (GMP) requirements, with product quality, manufacturing consistency, regulatory compliance, and production scalability representing essential service attributes. Manufacturing operations typically utilize stainless-steel or single-use bioreactor systems, supported by advanced purification technologies and automated process monitoring. The market serves clinical-stage biotechnology companies, established pharmaceutical manufacturers, and biological product developers seeking specialized production capacity, technical expertise, and reliable global manufacturing capabilities.

Key Findings
Biopharmaceutical Contract Manufacturing (BCMO) focuses on outsourced GMP production of biological drug substances and finished pharmaceutical products
Monoclonal antibodies and recombinant proteins form the established foundation of the global biological contract manufacturing industry
Commercial manufacturing provides recurring production demand supported by approved medicines and long-term pharmaceutical supply agreements
North America, Europe, and Asia-Pacific constitute the principal regional markets for biopharmaceutical manufacturing outsourcing services

Market Trends
The global Biopharmaceutical Contract Manufacturing (BCMO) industry is transitioning from conventional outsourced production toward integrated manufacturing partnerships covering multiple biological modalities, specialized technologies, and different stages of pharmaceutical development. Mammalian cell culture remains a foundational manufacturing platform for monoclonal antibodies and recombinant proteins, while increasingly complex biological products, including bispecific antibodies, ADCs, cell therapies, gene therapies, and nucleic acid therapeutics, are reshaping manufacturing requirements. Technological development is focused on high-productivity cell lines, intensified upstream processing, advanced purification systems, single-use bioreactors, automated process monitoring, and digital manufacturing management. These technologies support improvements in production efficiency, process consistency, and manufacturing flexibility. Pharmaceutical sponsors are placing greater emphasis on integrated manufacturing platforms capable of supporting projects from clinical development through commercial supply, reducing technology transfer complexity and improving continuity across the drug lifecycle. Manufacturing service providers are also strengthening analytical capabilities, quality management systems, and coordinated drug substance and drug product operations. Long-term industry development is increasingly characterized by technological specialization, manufacturing platform integration, and greater consideration of supply chain resilience in pharmaceutical outsourcing decisions.

Market Dynamics
Drivers
The primary growth drivers of Biopharmaceutical Contract Manufacturing (BCMO) include expanding biological drug development activities, increasing manufacturing complexity, and the growing strategic importance of pharmaceutical outsourcing. Biological medicines typically require specialized production facilities, validated manufacturing processes, highly trained personnel, and comprehensive quality management systems. These requirements create substantial technical and financial barriers for biotechnology companies seeking to establish independent production infrastructure. Contract manufacturing enables drug developers to access established GMP facilities, reduce capital expenditure, and adjust production requirements according to clinical development progress. Large pharmaceutical companies also engage external manufacturing partners to supplement internal capacity, support new product launches, diversify production networks, and maintain operational flexibility. Continued development of monoclonal antibodies, oncology biologics, immunological therapies, and advanced treatment modalities provides an expanding pipeline of potential manufacturing projects. Increasing regulatory attention to manufacturing consistency, product quality, and supply reliability further reinforces demand for experienced contract manufacturing organizations capable of supporting both clinical and commercial production.

Restraints
Biopharmaceutical Contract Manufacturing (BCMO) is constrained by substantial capital requirements, complex manufacturing validation procedures, specialized operating costs, and project-related demand uncertainty. Building GMP-compliant biological manufacturing facilities requires significant investment in cleanrooms, bioreactors, purification systems, analytical laboratories, contamination control infrastructure, and supporting utilities. Operating expenditure is influenced by skilled personnel costs, cell culture media, chromatography materials, single-use consumables, energy requirements, and extensive quality assurance activities. Manufacturing capacity expansion does not immediately generate corresponding revenue because new facilities must undergo qualification, customer technology transfers, process validation, and regulatory inspections before achieving stable utilization. In addition, clinical trial failures, pharmaceutical development delays, and changes in customer pipeline priorities can lead to production rescheduling or contract modifications. Biological manufacturing processes are often highly product-specific, making equipment and facility capacity less interchangeable than in conventional industrial manufacturing. These factors can create uneven utilization across manufacturing platforms and increase financial pressure on suppliers with limited customer diversification or insufficient commercial manufacturing contracts.

Opportunities
The Biopharmaceutical Contract Manufacturing (BCMO) market offers important opportunities in complex biological modalities, specialized manufacturing technologies, commercial production outsourcing, and geographically diversified supply networks. Increasing development activity involving bispecific and multispecific antibodies, ADCs, cell therapies, gene therapies, and nucleic acid therapeutics creates demand for differentiated manufacturing capabilities and specialized process expertise. Contract manufacturers offering integrated drug substance and drug product services can capture additional opportunities by supporting customer projects across successive development stages and into commercial production. Emerging biotechnology companies represent another important customer group because they frequently require flexible GMP capacity without committing to substantial manufacturing infrastructure investments. Technological opportunities are emerging from high-productivity cell culture platforms, intensified bioprocessing, modular facilities, automation, and advanced analytical technologies. Regional investment in manufacturing capacity across North America, Europe, and selected Asia-Pacific markets is also creating opportunities for facility expansion and international partnerships. Companies capable of combining specialized biological manufacturing expertise, regulatory compliance, efficient project execution, and dependable commercial supply are positioned to benefit from the increasing technical complexity of biological medicines.

Challenges
The principal challenges facing Biopharmaceutical Contract Manufacturing (BCMO) involve maintaining consistent product quality, ensuring regulatory compliance, managing manufacturing capacity, and adapting to technological changes across biological drug modalities. Biological processes are highly sensitive to variations in raw material quality, cell culture conditions, process parameters, equipment performance, and contamination control. Manufacturing deviations, unsuccessful validation campaigns, or product quality failures can result in production delays, batch losses, regulatory consequences, and significant financial exposure. The transition from clinical production to commercial manufacturing requires manufacturers to demonstrate process reproducibility, scalability, and reliable product quality under increasingly stringent operating conditions. At the same time, rapid development of advanced biological therapies requires substantial investment in specialized technologies whose future commercial demand remains uncertain. Manufacturers must balance expansion plans against clinical development risks, project cancellations, and potential underutilization of production assets. International manufacturing operations also face differences in regulatory requirements, trade policies, technology transfer procedures, and regional supply chain expectations. Maintaining qualified personnel, transparent quality systems, reliable project execution, and long-term customer relationships remains essential for sustainable competitiveness.

Industry Chain Analysis
The Biopharmaceutical Contract Manufacturing (BCMO) industry chain comprises upstream bioprocessing materials and equipment suppliers, midstream contract manufacturing service providers, and downstream pharmaceutical companies and biotechnology developers. Upstream participants supply cell culture media, feed supplements, chromatography resins, filtration membranes, single-use processing systems, bioreactors, analytical instruments, sterile containers, and specialized manufacturing components. Product quality and supply consistency are particularly important because biological manufacturing processes are sensitive to raw material variations and contamination risks. The increasing complexity of biological modalities also raises technical requirements for specialized processing materials, analytical methods, and production equipment.

Midstream activities represent the principal value creation stage, including cell cultivation, fermentation, harvesting, purification, bioconjugation, formulation, aseptic filling, manufacturing validation, and quality testing. Contract manufacturing organizations generate value through established GMP infrastructure, manufacturing technologies, regulatory expertise, production efficiency, and the ability to maintain reproducible product quality across multiple batches. Downstream customers include multinational pharmaceutical companies, emerging biotechnology firms, and other biological drug sponsors serving therapeutic markets such as oncology, immunology, infectious diseases, and genetic disorders. The industry's cost structure is influenced by facility depreciation, highly skilled labor, raw materials, manufacturing consumables, utilities, quality assurance, and regulatory compliance. Profitability depends on capacity utilization, manufacturing yields, production scale, customer contract structures, and the proportion of late-stage and commercial manufacturing activities. Long-term commercial contracts generally provide greater production visibility, while clinical-stage projects offer opportunities to establish relationships that may develop into recurring commercial manufacturing business.

Segment Insights
By biopharmaceutical modality, monoclonal and multispecific antibodies, together with other recombinant proteins, represent the established foundation of Biopharmaceutical Contract Manufacturing (BCMO). Antibody manufacturing benefits from relatively mature mammalian cell culture technologies, established purification processes, and extensive regulatory manufacturing experience. Within the broader market, complex antibody formats and ADCs are becoming increasingly important areas of technological differentiation, requiring specialized capabilities in protein expression, bioconjugation, high-containment processing, and analytical characterization. Cell and gene therapies represent technically demanding segments with specific requirements for viral vector production, cellular processing, sterility assurance, and small-batch manufacturing. Nucleic acid therapeutics and vaccines provide additional opportunities for specialized manufacturing platforms. The technical diversity of these products creates different manufacturing economics, operational risks, and entry barriers across market segments.

By manufacturing service type, drug substance production is a central part of the industry, covering upstream cultivation and downstream purification, while drug product manufacturing focuses on formulation, aseptic filling, lyophilization, and final dosage preparation. Integrated manufacturing arrangements coordinate both stages and may reduce project transfer complexity. Mammalian cell culture and microbial fermentation remain important established technologies, whereas viral production, cellular manufacturing, and bioconjugation platforms address more specialized requirements. Clinical-stage production emphasizes manufacturing flexibility, technical support, and rapid project execution, while Phase III and commercial manufacturing place greater importance on validated processes, batch consistency, regulatory readiness, and reliable capacity availability. Commercial projects can provide recurring manufacturing demand, although their financial contribution varies according to production volumes, contract terms, and facility utilization. Competitive positioning increasingly depends on the ability to support technically diverse projects while maintaining efficiency and quality across different manufacturing stages.

Downstream Market Opportunities
Downstream opportunities for Biopharmaceutical Contract Manufacturing (BCMO) are closely connected to pharmaceutical innovation, biological drug commercialization, and the diversification of therapeutic applications. Oncology represents an important source of manufacturing demand through monoclonal antibodies, bispecific antibodies, ADCs, and cellular immunotherapies. Immunology and autoimmune diseases support recurring production requirements for commercial antibody and recombinant protein treatments. Infectious disease prevention and treatment generate demand for vaccines and specialized biological medicines, while metabolic and endocrine diseases provide opportunities involving recombinant therapeutic proteins and other biological products. Rare and genetic diseases are particularly relevant to cell therapy, gene therapy, and viral vector manufacturing, where specialized technical capabilities and quality controls are required. Customer requirements also vary considerably: multinational pharmaceutical companies generally emphasize regulatory experience, supply reliability, production capacity, and long-term manufacturing partnerships, while emerging biotechnology companies prioritize flexibility, technical support, project execution speed, and access to commercial-scale manufacturing infrastructure. These differences create opportunities for both integrated international CDMOs and specialized manufacturers serving technically demanding biological drug categories.

Regional Insights
North America, Europe, and Asia-Pacific constitute the principal regional markets for Biopharmaceutical Contract Manufacturing (BCMO), supported by established pharmaceutical industries, advanced biotechnology ecosystems, and specialized manufacturing infrastructure. North America benefits from a substantial concentration of innovative pharmaceutical companies, biotechnology developers, and advanced therapy research organizations. The United States is an important source of outsourced manufacturing projects, particularly for innovative antibodies, oncology treatments, and emerging biological modalities. Europe maintains a strong manufacturing position through established GMP production networks, experienced technical personnel, mature regulatory systems, and specialized biological manufacturing facilities. Switzerland, Germany, and other European manufacturing locations support commercial biological production and complex contract manufacturing services.

Asia-Pacific plays an increasingly important role in the international biological manufacturing network. China has developed substantial capabilities in mammalian cell culture, antibody production, and complex biological manufacturing, supporting both domestic pharmaceutical developers and international customers. South Korea has established significant large-scale biologics manufacturing infrastructure, particularly in mammalian cell culture and commercial antibody production. Japan retains expertise in advanced bioprocessing technologies and specialized pharmaceutical manufacturing, while India and other emerging Asian markets offer additional opportunities associated with biotechnology development and GMP infrastructure investment. Regional competition is influenced by manufacturing economics, regulatory recognition, technical capabilities, customer relationships, and supply chain localization strategies. Pharmaceutical companies are increasingly evaluating geographical diversification and alternative manufacturing arrangements to strengthen supply continuity, creating opportunities for established global providers as well as regional manufacturers with qualified facilities and reliable production capabilities.

Competitive Landscape Analysis
The global Biopharmaceutical Contract Manufacturing (BCMO) market features competition among large integrated CDMOs, specialized biologics manufacturers, pharmaceutical companies providing third-party manufacturing services, and technology-focused providers serving emerging biological modalities. Lonza, Samsung Biologics, WuXi Biologics, FUJIFILM Holdings through its biologics manufacturing operations, AGC through AGC Biologics, and Boehringer Ingelheim through BioXcellence represent important participants with established manufacturing capabilities and international customer relationships. Lonza competes through integrated biologics services, manufacturing technology, and commercial production expertise, while Samsung Biologics emphasizes large-scale mammalian cell culture capacity, operational execution, and long-term pharmaceutical supply partnerships. WuXi Biologics combines biological development and manufacturing capabilities with an extensive project portfolio covering antibodies and complex biological products. In 2025, WuXi Biologics reported 945 integrated projects, including 74 Phase III projects and 25 commercial manufacturing projects. Its 2025 project additions were increasingly concentrated in bispecific antibodies and ADCs, reflecting the commercial importance of complex biological modalities.

Other participants, including Rentschler Biopharma, KBI Biopharma, LOTTE BIOLOGICS, and specialized manufacturers in antibody conjugation, viral vectors, and cell therapy, compete through technical expertise, regulatory experience, manufacturing quality, and customer-specific production solutions. The industry is increasingly characterized by competition in manufacturing productivity, technology transfer performance, regulatory compliance, commercial capacity utilization, and long-term customer retention. Strategic investment is focused on integrated manufacturing platforms, specialized technology capabilities, flexible production infrastructure, and geographically diversified supply networks, with manufacturers seeking to establish enduring relationships with pharmaceutical sponsors throughout the biological drug lifecycle.

Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Biopharmaceutical Contract Manufacturing (BCMO) market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
Lonza Group AG
Samsung Biologics Co., Ltd.
WuXi Biologics (Cayman) Inc.
FUJIFILM Holdings Corporation
AGC Inc.
Boehringer Ingelheim International GmbH
Thermo Fisher Scientific Inc.
Novo Holdings A/S
Rentschler Biopharma SE
KBI Biopharma, Inc.
Ajinomoto Co., Inc.
LOTTE BIOLOGICS
Polpharma Biologics
EirGenix, Inc.
Richter-Helm BioLogics GmbH & Co. KG
Simtra BioPharma Solutions
Vetter Pharma-Fertigung GmbH & Co. KG
Piramal Pharma Limited
AbbVie Inc.
Emergent BioSolutions Inc.
SK pharmteco
Oxford Biomedica plc
WuXi XDC Cayman Inc.
Porton Pharma Solutions Ltd.
Asymchem Laboratories (Tianjin) Co., Ltd.
BioVectra Inc.
Bora Pharmaceuticals Co., Ltd.
Recipharm AB
Minaris Regenerative Medicine
Cellipont Bioservices
Andelyn Biosciences
Danaher Corporation
BioCina
Syngene International Limited
Aragen Life Sciences
MabPlex International
GenScript Biotech Corporation
Chime Biologics
Hangzhou HJB
BiBo Pharma

Segment by Type
Monoclonal and Multispecific Antibodies
Antibody-Drug Conjugates (ADCs)
Vaccines
Cell Therapy Products
Gene Therapy and Viral Vector Products
Nucleic Acid Therapeutics
Others

Segment by Manufacturing Service Type
Drug Substance Manufacturing
Drug Product Manufacturing
Integrated Drug Substance and Drug Product Manufacturing
Others

Segment by Development and Commercialization Stage
Preclinical and IND-enabling Manufacturing
Phase I Clinical Manufacturing
Phase II Clinical Manufacturing
Phase III Clinical Manufacturing
Others

Segment by Application
Bio-Pharmaceutical Companies
Pharmaceutical Companies
Drug Discovery Companies
Others

Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA

Chapter Outline
Chapter 1: Defines the Biopharmaceutical Contract Manufacturing (BCMO) study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.

Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る


Table of Contents

1 Study Coverage
1.1 Introduction to Biopharmaceutical Contract Manufacturing (BCMO): Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Monoclonal and Multispecific Antibodies
1.2.3 Antibody-Drug Conjugates (ADCs)
1.2.4 Vaccines
1.2.5 Cell Therapy Products
1.2.6 Gene Therapy and Viral Vector Products
1.2.7 Nucleic Acid Therapeutics
1.2.8 Others
1.3 Market Segmentation by Manufacturing Service Type
1.3.1 Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size by Manufacturing Service Type, 2021 vs 2025 vs 2032
1.3.2 Drug Substance Manufacturing
1.3.3 Drug Product Manufacturing
1.3.4 Integrated Drug Substance and Drug Product Manufacturing
1.3.5 Others
1.4 Market Segmentation by Development and Commercialization Stage
1.4.1 Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size by Development and Commercialization Stage, 2021 vs 2025 vs 2032
1.4.2 Preclinical and IND-enabling Manufacturing
1.4.3 Phase I Clinical Manufacturing
1.4.4 Phase II Clinical Manufacturing
1.4.5 Phase III Clinical Manufacturing
1.4.6 Others
1.5 Market Segmentation by Application
1.5.1 Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Bio-Pharmaceutical Companies
1.5.3 Pharmaceutical Companies
1.5.4 Drug Discovery Companies
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue Estimates and Forecasts (2021-2032)
2.2 Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Biopharmaceutical Contract Manufacturing (BCMO) Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Biopharmaceutical Contract Manufacturing (BCMO) Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Monoclonal and Multispecific Antibodies: Market Share by Key Players
3.3.2 Antibody-Drug Conjugates (ADCs): Market Share by Key Players
3.3.3 Vaccines: Market Share by Key Players
3.3.4 Cell Therapy Products: Market Share by Key Players
3.3.5 Gene Therapy and Viral Vector Products: Market Share by Key Players
3.3.6 Nucleic Acid Therapeutics: Market Share by Key Players
3.3.7 Others: Market Share by Key Players
3.4 Global Biopharmaceutical Contract Manufacturing (BCMO) Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Biopharmaceutical Contract Manufacturing (BCMO) Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Biopharmaceutical Contract Manufacturing (BCMO) Market by Manufacturing Service Type
4.2.1 Global Revenue by Manufacturing Service Type (2021-2032)
4.2.2 Global Revenue-Based Market Share by Manufacturing Service Type (2021-2032)
4.3 Global Biopharmaceutical Contract Manufacturing (BCMO) Market by Development and Commercialization Stage
4.3.1 Global Revenue by Development and Commercialization Stage (2021-2032)
4.3.2 Global Revenue-Based Market Share by Development and Commercialization Stage (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Biopharmaceutical Contract Manufacturing (BCMO) Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Biopharmaceutical Contract Manufacturing (BCMO) Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Biopharmaceutical Contract Manufacturing (BCMO) Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Biopharmaceutical Contract Manufacturing (BCMO) Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Biopharmaceutical Contract Manufacturing (BCMO) Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Biopharmaceutical Contract Manufacturing (BCMO) Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Biopharmaceutical Contract Manufacturing (BCMO) Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Biopharmaceutical Contract Manufacturing (BCMO) Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Biopharmaceutical Contract Manufacturing (BCMO) Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Biopharmaceutical Contract Manufacturing (BCMO) Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Lonza Group AG
11.1.1 Lonza Group AG Corporation Information
11.1.2 Lonza Group AG Business Overview
11.1.3 Lonza Group AG Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.1.4 Lonza Group AG Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.1.5 Lonza Group AG Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Product in 2025
11.1.6 Lonza Group AG Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Application in 2025
11.1.7 Lonza Group AG Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Geographic Area in 2025
11.1.8 Lonza Group AG Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
11.1.9 Lonza Group AG Recent Developments
11.2 Samsung Biologics Co., Ltd.
11.2.1 Samsung Biologics Co., Ltd. Corporation Information
11.2.2 Samsung Biologics Co., Ltd. Business Overview
11.2.3 Samsung Biologics Co., Ltd. Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.2.4 Samsung Biologics Co., Ltd. Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.2.5 Samsung Biologics Co., Ltd. Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Product in 2025
11.2.6 Samsung Biologics Co., Ltd. Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Application in 2025
11.2.7 Samsung Biologics Co., Ltd. Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Geographic Area in 2025
11.2.8 Samsung Biologics Co., Ltd. Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
11.2.9 Samsung Biologics Co., Ltd. Recent Developments
11.3 WuXi Biologics (Cayman) Inc.
11.3.1 WuXi Biologics (Cayman) Inc. Corporation Information
11.3.2 WuXi Biologics (Cayman) Inc. Business Overview
11.3.3 WuXi Biologics (Cayman) Inc. Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.3.4 WuXi Biologics (Cayman) Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.3.5 WuXi Biologics (Cayman) Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Product in 2025
11.3.6 WuXi Biologics (Cayman) Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Application in 2025
11.3.7 WuXi Biologics (Cayman) Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Geographic Area in 2025
11.3.8 WuXi Biologics (Cayman) Inc. Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
11.3.9 WuXi Biologics (Cayman) Inc. Recent Developments
11.4 FUJIFILM Holdings Corporation
11.4.1 FUJIFILM Holdings Corporation Corporation Information
11.4.2 FUJIFILM Holdings Corporation Business Overview
11.4.3 FUJIFILM Holdings Corporation Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.4.4 FUJIFILM Holdings Corporation Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.4.5 FUJIFILM Holdings Corporation Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Product in 2025
11.4.6 FUJIFILM Holdings Corporation Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Application in 2025
11.4.7 FUJIFILM Holdings Corporation Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Geographic Area in 2025
11.4.8 FUJIFILM Holdings Corporation Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
11.4.9 FUJIFILM Holdings Corporation Recent Developments
11.5 AGC Inc.
11.5.1 AGC Inc. Corporation Information
11.5.2 AGC Inc. Business Overview
11.5.3 AGC Inc. Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.5.4 AGC Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.5.5 AGC Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Product in 2025
11.5.6 AGC Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Application in 2025
11.5.7 AGC Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Geographic Area in 2025
11.5.8 AGC Inc. Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
11.5.9 AGC Inc. Recent Developments
11.6 Boehringer Ingelheim International GmbH
11.6.1 Boehringer Ingelheim International GmbH Corporation Information
11.6.2 Boehringer Ingelheim International GmbH Business Overview
11.6.3 Boehringer Ingelheim International GmbH Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.6.4 Boehringer Ingelheim International GmbH Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.6.5 Boehringer Ingelheim International GmbH Recent Developments
11.7 Thermo Fisher Scientific Inc.
11.7.1 Thermo Fisher Scientific Inc. Corporation Information
11.7.2 Thermo Fisher Scientific Inc. Business Overview
11.7.3 Thermo Fisher Scientific Inc. Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.7.4 Thermo Fisher Scientific Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.7.5 Thermo Fisher Scientific Inc. Recent Developments
11.8 Novo Holdings A/S
11.8.1 Novo Holdings A/S Corporation Information
11.8.2 Novo Holdings A/S Business Overview
11.8.3 Novo Holdings A/S Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.8.4 Novo Holdings A/S Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.8.5 Novo Holdings A/S Recent Developments
11.9 Rentschler Biopharma SE
11.9.1 Rentschler Biopharma SE Corporation Information
11.9.2 Rentschler Biopharma SE Business Overview
11.9.3 Rentschler Biopharma SE Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.9.4 Rentschler Biopharma SE Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.9.5 Rentschler Biopharma SE Recent Developments
11.10 KBI Biopharma, Inc.
11.10.1 KBI Biopharma, Inc. Corporation Information
11.10.2 KBI Biopharma, Inc. Business Overview
11.10.3 KBI Biopharma, Inc. Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.10.4 KBI Biopharma, Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Ajinomoto Co., Inc.
11.11.1 Ajinomoto Co., Inc. Corporation Information
11.11.2 Ajinomoto Co., Inc. Business Overview
11.11.3 Ajinomoto Co., Inc. Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.11.4 Ajinomoto Co., Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.11.5 Ajinomoto Co., Inc. Recent Developments
11.12 LOTTE BIOLOGICS
11.12.1 LOTTE BIOLOGICS Corporation Information
11.12.2 LOTTE BIOLOGICS Business Overview
11.12.3 LOTTE BIOLOGICS Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.12.4 LOTTE BIOLOGICS Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.12.5 LOTTE BIOLOGICS Recent Developments
11.13 Polpharma Biologics
11.13.1 Polpharma Biologics Corporation Information
11.13.2 Polpharma Biologics Business Overview
11.13.3 Polpharma Biologics Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.13.4 Polpharma Biologics Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.13.5 Polpharma Biologics Recent Developments
11.14 EirGenix, Inc.
11.14.1 EirGenix, Inc. Corporation Information
11.14.2 EirGenix, Inc. Business Overview
11.14.3 EirGenix, Inc. Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.14.4 EirGenix, Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.14.5 EirGenix, Inc. Recent Developments
11.15 Richter-Helm BioLogics GmbH & Co. KG
11.15.1 Richter-Helm BioLogics GmbH & Co. KG Corporation Information
11.15.2 Richter-Helm BioLogics GmbH & Co. KG Business Overview
11.15.3 Richter-Helm BioLogics GmbH & Co. KG Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.15.4 Richter-Helm BioLogics GmbH & Co. KG Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.15.5 Richter-Helm BioLogics GmbH & Co. KG Recent Developments
11.16 Simtra BioPharma Solutions
11.16.1 Simtra BioPharma Solutions Corporation Information
11.16.2 Simtra BioPharma Solutions Business Overview
11.16.3 Simtra BioPharma Solutions Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.16.4 Simtra BioPharma Solutions Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.16.5 Simtra BioPharma Solutions Recent Developments
11.17 Vetter Pharma-Fertigung GmbH & Co. KG
11.17.1 Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information
11.17.2 Vetter Pharma-Fertigung GmbH & Co. KG Business Overview
11.17.3 Vetter Pharma-Fertigung GmbH & Co. KG Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.17.4 Vetter Pharma-Fertigung GmbH & Co. KG Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.17.5 Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments
11.18 Piramal Pharma Limited
11.18.1 Piramal Pharma Limited Corporation Information
11.18.2 Piramal Pharma Limited Business Overview
11.18.3 Piramal Pharma Limited Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.18.4 Piramal Pharma Limited Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.18.5 Piramal Pharma Limited Recent Developments
11.19 AbbVie Inc.
11.19.1 AbbVie Inc. Corporation Information
11.19.2 AbbVie Inc. Business Overview
11.19.3 AbbVie Inc. Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.19.4 AbbVie Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.19.5 AbbVie Inc. Recent Developments
11.20 Emergent BioSolutions Inc.
11.20.1 Emergent BioSolutions Inc. Corporation Information
11.20.2 Emergent BioSolutions Inc. Business Overview
11.20.3 Emergent BioSolutions Inc. Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.20.4 Emergent BioSolutions Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.20.5 Emergent BioSolutions Inc. Recent Developments
11.21 SK pharmteco
11.21.1 SK pharmteco Corporation Information
11.21.2 SK pharmteco Business Overview
11.21.3 SK pharmteco Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.21.4 SK pharmteco Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.21.5 SK pharmteco Recent Developments
11.22 Oxford Biomedica plc
11.22.1 Oxford Biomedica plc Corporation Information
11.22.2 Oxford Biomedica plc Business Overview
11.22.3 Oxford Biomedica plc Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.22.4 Oxford Biomedica plc Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.22.5 Oxford Biomedica plc Recent Developments
11.23 WuXi XDC Cayman Inc.
11.23.1 WuXi XDC Cayman Inc. Corporation Information
11.23.2 WuXi XDC Cayman Inc. Business Overview
11.23.3 WuXi XDC Cayman Inc. Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.23.4 WuXi XDC Cayman Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.23.5 WuXi XDC Cayman Inc. Recent Developments
11.24 Porton Pharma Solutions Ltd.
11.24.1 Porton Pharma Solutions Ltd. Corporation Information
11.24.2 Porton Pharma Solutions Ltd. Business Overview
11.24.3 Porton Pharma Solutions Ltd. Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.24.4 Porton Pharma Solutions Ltd. Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.24.5 Porton Pharma Solutions Ltd. Recent Developments
11.25 Asymchem Laboratories (Tianjin) Co., Ltd.
11.25.1 Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information
11.25.2 Asymchem Laboratories (Tianjin) Co., Ltd. Business Overview
11.25.3 Asymchem Laboratories (Tianjin) Co., Ltd. Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.25.4 Asymchem Laboratories (Tianjin) Co., Ltd. Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.25.5 Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments
11.26 BioVectra Inc.
11.26.1 BioVectra Inc. Corporation Information
11.26.2 BioVectra Inc. Business Overview
11.26.3 BioVectra Inc. Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.26.4 BioVectra Inc. Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.26.5 BioVectra Inc. Recent Developments
11.27 Bora Pharmaceuticals Co., Ltd.
11.27.1 Bora Pharmaceuticals Co., Ltd. Corporation Information
11.27.2 Bora Pharmaceuticals Co., Ltd. Business Overview
11.27.3 Bora Pharmaceuticals Co., Ltd. Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.27.4 Bora Pharmaceuticals Co., Ltd. Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.27.5 Bora Pharmaceuticals Co., Ltd. Recent Developments
11.28 Recipharm AB
11.28.1 Recipharm AB Corporation Information
11.28.2 Recipharm AB Business Overview
11.28.3 Recipharm AB Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.28.4 Recipharm AB Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.28.5 Recipharm AB Recent Developments
11.29 Minaris Regenerative Medicine
11.29.1 Minaris Regenerative Medicine Corporation Information
11.29.2 Minaris Regenerative Medicine Business Overview
11.29.3 Minaris Regenerative Medicine Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.29.4 Minaris Regenerative Medicine Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.29.5 Minaris Regenerative Medicine Recent Developments
11.30 Cellipont Bioservices
11.30.1 Cellipont Bioservices Corporation Information
11.30.2 Cellipont Bioservices Business Overview
11.30.3 Cellipont Bioservices Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.30.4 Cellipont Bioservices Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.30.5 Cellipont Bioservices Recent Developments
11.31 Andelyn Biosciences
11.31.1 Andelyn Biosciences Corporation Information
11.31.2 Andelyn Biosciences Business Overview
11.31.3 Andelyn Biosciences Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.31.4 Andelyn Biosciences Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.31.5 Andelyn Biosciences Recent Developments
11.32 Danaher Corporation
11.32.1 Danaher Corporation Corporation Information
11.32.2 Danaher Corporation Business Overview
11.32.3 Danaher Corporation Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.32.4 Danaher Corporation Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.32.5 Danaher Corporation Recent Developments
11.33 BioCina
11.33.1 BioCina Corporation Information
11.33.2 BioCina Business Overview
11.33.3 BioCina Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.33.4 BioCina Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.33.5 BioCina Recent Developments
11.34 Syngene International Limited
11.34.1 Syngene International Limited Corporation Information
11.34.2 Syngene International Limited Business Overview
11.34.3 Syngene International Limited Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.34.4 Syngene International Limited Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.34.5 Syngene International Limited Recent Developments
11.35 Aragen Life Sciences
11.35.1 Aragen Life Sciences Corporation Information
11.35.2 Aragen Life Sciences Business Overview
11.35.3 Aragen Life Sciences Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.35.4 Aragen Life Sciences Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.35.5 Aragen Life Sciences Recent Developments
11.36 MabPlex International
11.36.1 MabPlex International Corporation Information
11.36.2 MabPlex International Business Overview
11.36.3 MabPlex International Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.36.4 MabPlex International Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.36.5 MabPlex International Recent Developments
11.37 GenScript Biotech Corporation
11.37.1 GenScript Biotech Corporation Corporation Information
11.37.2 GenScript Biotech Corporation Business Overview
11.37.3 GenScript Biotech Corporation Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.37.4 GenScript Biotech Corporation Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.37.5 GenScript Biotech Corporation Recent Developments
11.38 Chime Biologics
11.38.1 Chime Biologics Corporation Information
11.38.2 Chime Biologics Business Overview
11.38.3 Chime Biologics Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.38.4 Chime Biologics Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.38.5 Chime Biologics Recent Developments
11.39 Hangzhou HJB
11.39.1 Hangzhou HJB Corporation Information
11.39.2 Hangzhou HJB Business Overview
11.39.3 Hangzhou HJB Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.39.4 Hangzhou HJB Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.39.5 Hangzhou HJB Recent Developments
11.40 BiBo Pharma
11.40.1 BiBo Pharma Corporation Information
11.40.2 BiBo Pharma Business Overview
11.40.3 BiBo Pharma Biopharmaceutical Contract Manufacturing (BCMO) Product Features and Attributes
11.40.4 BiBo Pharma Biopharmaceutical Contract Manufacturing (BCMO) Revenue and Gross Margin (2021-2026)
11.40.5 BiBo Pharma Recent Developments

12 Biopharmaceutical Contract Manufacturing (BCMO) Value Chain and Ecosystem Analysis
12.1 Biopharmaceutical Contract Manufacturing (BCMO) Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Biopharmaceutical Contract Manufacturing (BCMO) Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Biopharmaceutical Contract Manufacturing (BCMO) Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る



List of Tables/Graphs

List of Tables
Table 1. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Manufacturing Service Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Region (US$ Million), 2021-2026
Table 7. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Players (US$ Million), 2021-2026
Table 10. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Biopharmaceutical Contract Manufacturing (BCMO) Revenue, 2025
Table 13. Global Biopharmaceutical Contract Manufacturing (BCMO) Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Biopharmaceutical Contract Manufacturing (BCMO) Companies Headquarters
Table 15. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Type (US$ Million), 2021-2026
Table 19. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Type (US$ Million), 2027-2032
Table 20. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Manufacturing Service Type (US$ Million), 2021-2026
Table 21. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Manufacturing Service Type (US$ Million), 2027-2032
Table 22. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Development and Commercialization Stage (US$ Million), 2021-2026
Table 23. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Development and Commercialization Stage (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Application (US$ Million), 2021-2026
Table 26. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue by Application (US$ Million), 2027-2032
Table 27. Biopharmaceutical Contract Manufacturing (BCMO) High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Biopharmaceutical Contract Manufacturing (BCMO) Growth Accelerators and Market Barriers
Table 31. North America Biopharmaceutical Contract Manufacturing (BCMO) Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Biopharmaceutical Contract Manufacturing (BCMO) Growth Accelerators and Market Barriers
Table 33. Europe Biopharmaceutical Contract Manufacturing (BCMO) Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Biopharmaceutical Contract Manufacturing (BCMO) Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Biopharmaceutical Contract Manufacturing (BCMO) Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Biopharmaceutical Contract Manufacturing (BCMO) Investment Opportunities and Key Challenges
Table 37. Central and South America Biopharmaceutical Contract Manufacturing (BCMO) Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Biopharmaceutical Contract Manufacturing (BCMO) Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Biopharmaceutical Contract Manufacturing (BCMO) Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Lonza Group AG Corporation Information
Table 41. Lonza Group AG Description and Major Businesses
Table 42. Lonza Group AG Product Features and Attributes
Table 43. Lonza Group AG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Lonza Group AG Revenue Proportion by Product in 2025
Table 45. Lonza Group AG Revenue Proportion by Application in 2025
Table 46. Lonza Group AG Revenue Proportion by Geographic Area in 2025
Table 47. Lonza Group AG Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
Table 48. Lonza Group AG Recent Developments
Table 49. Samsung Biologics Co., Ltd. Corporation Information
Table 50. Samsung Biologics Co., Ltd. Description and Major Businesses
Table 51. Samsung Biologics Co., Ltd. Product Features and Attributes
Table 52. Samsung Biologics Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Samsung Biologics Co., Ltd. Revenue Proportion by Product in 2025
Table 54. Samsung Biologics Co., Ltd. Revenue Proportion by Application in 2025
Table 55. Samsung Biologics Co., Ltd. Revenue Proportion by Geographic Area in 2025
Table 56. Samsung Biologics Co., Ltd. Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
Table 57. Samsung Biologics Co., Ltd. Recent Developments
Table 58. WuXi Biologics (Cayman) Inc. Corporation Information
Table 59. WuXi Biologics (Cayman) Inc. Description and Major Businesses
Table 60. WuXi Biologics (Cayman) Inc. Product Features and Attributes
Table 61. WuXi Biologics (Cayman) Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. WuXi Biologics (Cayman) Inc. Revenue Proportion by Product in 2025
Table 63. WuXi Biologics (Cayman) Inc. Revenue Proportion by Application in 2025
Table 64. WuXi Biologics (Cayman) Inc. Revenue Proportion by Geographic Area in 2025
Table 65. WuXi Biologics (Cayman) Inc. Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
Table 66. WuXi Biologics (Cayman) Inc. Recent Developments
Table 67. FUJIFILM Holdings Corporation Corporation Information
Table 68. FUJIFILM Holdings Corporation Description and Major Businesses
Table 69. FUJIFILM Holdings Corporation Product Features and Attributes
Table 70. FUJIFILM Holdings Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. FUJIFILM Holdings Corporation Revenue Proportion by Product in 2025
Table 72. FUJIFILM Holdings Corporation Revenue Proportion by Application in 2025
Table 73. FUJIFILM Holdings Corporation Revenue Proportion by Geographic Area in 2025
Table 74. FUJIFILM Holdings Corporation Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
Table 75. FUJIFILM Holdings Corporation Recent Developments
Table 76. AGC Inc. Corporation Information
Table 77. AGC Inc. Description and Major Businesses
Table 78. AGC Inc. Product Features and Attributes
Table 79. AGC Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. AGC Inc. Revenue Proportion by Product in 2025
Table 81. AGC Inc. Revenue Proportion by Application in 2025
Table 82. AGC Inc. Revenue Proportion by Geographic Area in 2025
Table 83. AGC Inc. Biopharmaceutical Contract Manufacturing (BCMO) SWOT Analysis
Table 84. AGC Inc. Recent Developments
Table 85. Boehringer Ingelheim International GmbH Corporation Information
Table 86. Boehringer Ingelheim International GmbH Description and Major Businesses
Table 87. Boehringer Ingelheim International GmbH Product Features and Attributes
Table 88. Boehringer Ingelheim International GmbH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Boehringer Ingelheim International GmbH Recent Developments
Table 90. Thermo Fisher Scientific Inc. Corporation Information
Table 91. Thermo Fisher Scientific Inc. Description and Major Businesses
Table 92. Thermo Fisher Scientific Inc. Product Features and Attributes
Table 93. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Thermo Fisher Scientific Inc. Recent Developments
Table 95. Novo Holdings A/S Corporation Information
Table 96. Novo Holdings A/S Description and Major Businesses
Table 97. Novo Holdings A/S Product Features and Attributes
Table 98. Novo Holdings A/S Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Novo Holdings A/S Recent Developments
Table 100. Rentschler Biopharma SE Corporation Information
Table 101. Rentschler Biopharma SE Description and Major Businesses
Table 102. Rentschler Biopharma SE Product Features and Attributes
Table 103. Rentschler Biopharma SE Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Rentschler Biopharma SE Recent Developments
Table 105. KBI Biopharma, Inc. Corporation Information
Table 106. KBI Biopharma, Inc. Description and Major Businesses
Table 107. KBI Biopharma, Inc. Product Features and Attributes
Table 108. KBI Biopharma, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. KBI Biopharma, Inc. Recent Developments
Table 110. Ajinomoto Co., Inc. Corporation Information
Table 111. Ajinomoto Co., Inc. Description and Major Businesses
Table 112. Ajinomoto Co., Inc. Product Features and Attributes
Table 113. Ajinomoto Co., Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Ajinomoto Co., Inc. Recent Developments
Table 115. LOTTE BIOLOGICS Corporation Information
Table 116. LOTTE BIOLOGICS Description and Major Businesses
Table 117. LOTTE BIOLOGICS Product Features and Attributes
Table 118. LOTTE BIOLOGICS Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. LOTTE BIOLOGICS Recent Developments
Table 120. Polpharma Biologics Corporation Information
Table 121. Polpharma Biologics Description and Major Businesses
Table 122. Polpharma Biologics Product Features and Attributes
Table 123. Polpharma Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Polpharma Biologics Recent Developments
Table 125. EirGenix, Inc. Corporation Information
Table 126. EirGenix, Inc. Description and Major Businesses
Table 127. EirGenix, Inc. Product Features and Attributes
Table 128. EirGenix, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. EirGenix, Inc. Recent Developments
Table 130. Richter-Helm BioLogics GmbH & Co. KG Corporation Information
Table 131. Richter-Helm BioLogics GmbH & Co. KG Description and Major Businesses
Table 132. Richter-Helm BioLogics GmbH & Co. KG Product Features and Attributes
Table 133. Richter-Helm BioLogics GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Richter-Helm BioLogics GmbH & Co. KG Recent Developments
Table 135. Simtra BioPharma Solutions Corporation Information
Table 136. Simtra BioPharma Solutions Description and Major Businesses
Table 137. Simtra BioPharma Solutions Product Features and Attributes
Table 138. Simtra BioPharma Solutions Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Simtra BioPharma Solutions Recent Developments
Table 140. Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information
Table 141. Vetter Pharma-Fertigung GmbH & Co. KG Description and Major Businesses
Table 142. Vetter Pharma-Fertigung GmbH & Co. KG Product Features and Attributes
Table 143. Vetter Pharma-Fertigung GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments
Table 145. Piramal Pharma Limited Corporation Information
Table 146. Piramal Pharma Limited Description and Major Businesses
Table 147. Piramal Pharma Limited Product Features and Attributes
Table 148. Piramal Pharma Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Piramal Pharma Limited Recent Developments
Table 150. AbbVie Inc. Corporation Information
Table 151. AbbVie Inc. Description and Major Businesses
Table 152. AbbVie Inc. Product Features and Attributes
Table 153. AbbVie Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. AbbVie Inc. Recent Developments
Table 155. Emergent BioSolutions Inc. Corporation Information
Table 156. Emergent BioSolutions Inc. Description and Major Businesses
Table 157. Emergent BioSolutions Inc. Product Features and Attributes
Table 158. Emergent BioSolutions Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Emergent BioSolutions Inc. Recent Developments
Table 160. SK pharmteco Corporation Information
Table 161. SK pharmteco Description and Major Businesses
Table 162. SK pharmteco Product Features and Attributes
Table 163. SK pharmteco Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. SK pharmteco Recent Developments
Table 165. Oxford Biomedica plc Corporation Information
Table 166. Oxford Biomedica plc Description and Major Businesses
Table 167. Oxford Biomedica plc Product Features and Attributes
Table 168. Oxford Biomedica plc Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. Oxford Biomedica plc Recent Developments
Table 170. WuXi XDC Cayman Inc. Corporation Information
Table 171. WuXi XDC Cayman Inc. Description and Major Businesses
Table 172. WuXi XDC Cayman Inc. Product Features and Attributes
Table 173. WuXi XDC Cayman Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. WuXi XDC Cayman Inc. Recent Developments
Table 175. Porton Pharma Solutions Ltd. Corporation Information
Table 176. Porton Pharma Solutions Ltd. Description and Major Businesses
Table 177. Porton Pharma Solutions Ltd. Product Features and Attributes
Table 178. Porton Pharma Solutions Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Porton Pharma Solutions Ltd. Recent Developments
Table 180. Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information
Table 181. Asymchem Laboratories (Tianjin) Co., Ltd. Description and Major Businesses
Table 182. Asymchem Laboratories (Tianjin) Co., Ltd. Product Features and Attributes
Table 183. Asymchem Laboratories (Tianjin) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments
Table 185. BioVectra Inc. Corporation Information
Table 186. BioVectra Inc. Description and Major Businesses
Table 187. BioVectra Inc. Product Features and Attributes
Table 188. BioVectra Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. BioVectra Inc. Recent Developments
Table 190. Bora Pharmaceuticals Co., Ltd. Corporation Information
Table 191. Bora Pharmaceuticals Co., Ltd. Description and Major Businesses
Table 192. Bora Pharmaceuticals Co., Ltd. Product Features and Attributes
Table 193. Bora Pharmaceuticals Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Bora Pharmaceuticals Co., Ltd. Recent Developments
Table 195. Recipharm AB Corporation Information
Table 196. Recipharm AB Description and Major Businesses
Table 197. Recipharm AB Product Features and Attributes
Table 198. Recipharm AB Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. Recipharm AB Recent Developments
Table 200. Minaris Regenerative Medicine Corporation Information
Table 201. Minaris Regenerative Medicine Description and Major Businesses
Table 202. Minaris Regenerative Medicine Product Features and Attributes
Table 203. Minaris Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. Minaris Regenerative Medicine Recent Developments
Table 205. Cellipont Bioservices Corporation Information
Table 206. Cellipont Bioservices Description and Major Businesses
Table 207. Cellipont Bioservices Product Features and Attributes
Table 208. Cellipont Bioservices Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. Cellipont Bioservices Recent Developments
Table 210. Andelyn Biosciences Corporation Information
Table 211. Andelyn Biosciences Description and Major Businesses
Table 212. Andelyn Biosciences Product Features and Attributes
Table 213. Andelyn Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 214. Andelyn Biosciences Recent Developments
Table 215. Danaher Corporation Corporation Information
Table 216. Danaher Corporation Description and Major Businesses
Table 217. Danaher Corporation Product Features and Attributes
Table 218. Danaher Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 219. Danaher Corporation Recent Developments
Table 220. BioCina Corporation Information
Table 221. BioCina Description and Major Businesses
Table 222. BioCina Product Features and Attributes
Table 223. BioCina Revenue (US$ Million) and Gross Margin (2021-2026)
Table 224. BioCina Recent Developments
Table 225. Syngene International Limited Corporation Information
Table 226. Syngene International Limited Description and Major Businesses
Table 227. Syngene International Limited Product Features and Attributes
Table 228. Syngene International Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 229. Syngene International Limited Recent Developments
Table 230. Aragen Life Sciences Corporation Information
Table 231. Aragen Life Sciences Description and Major Businesses
Table 232. Aragen Life Sciences Product Features and Attributes
Table 233. Aragen Life Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 234. Aragen Life Sciences Recent Developments
Table 235. MabPlex International Corporation Information
Table 236. MabPlex International Description and Major Businesses
Table 237. MabPlex International Product Features and Attributes
Table 238. MabPlex International Revenue (US$ Million) and Gross Margin (2021-2026)
Table 239. MabPlex International Recent Developments
Table 240. GenScript Biotech Corporation Corporation Information
Table 241. GenScript Biotech Corporation Description and Major Businesses
Table 242. GenScript Biotech Corporation Product Features and Attributes
Table 243. GenScript Biotech Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 244. GenScript Biotech Corporation Recent Developments
Table 245. Chime Biologics Corporation Information
Table 246. Chime Biologics Description and Major Businesses
Table 247. Chime Biologics Product Features and Attributes
Table 248. Chime Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 249. Chime Biologics Recent Developments
Table 250. Hangzhou HJB Corporation Information
Table 251. Hangzhou HJB Description and Major Businesses
Table 252. Hangzhou HJB Product Features and Attributes
Table 253. Hangzhou HJB Revenue (US$ Million) and Gross Margin (2021-2026)
Table 254. Hangzhou HJB Recent Developments
Table 255. BiBo Pharma Corporation Information
Table 256. BiBo Pharma Description and Major Businesses
Table 257. BiBo Pharma Product Features and Attributes
Table 258. BiBo Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 259. BiBo Pharma Recent Developments
Table 260. Technologies, Platforms and Infrastructure
Table 261. Distributors List
Table 262. Market Trends and Market Evolution
Table 263. Market Drivers and Opportunities
Table 264. Market Challenges, Risks, and Restraints
Table 265. Research Programs/Design for This Report
Table 266. Key Data Information from Secondary Sources
Table 267. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Monoclonal and Multispecific Antibodies Product Picture
Figure 3. Antibody-Drug Conjugates (ADCs) Product Picture
Figure 4. Vaccines Product Picture
Figure 5. Cell Therapy Products Product Picture
Figure 6. Gene Therapy and Viral Vector Products Product Picture
Figure 7. Nucleic Acid Therapeutics Product Picture
Figure 8. Others Product Picture
Figure 9. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Manufacturing Service Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 10. Drug Substance Manufacturing Product Picture
Figure 11. Drug Product Manufacturing Product Picture
Figure 12. Integrated Drug Substance and Drug Product Manufacturing Product Picture
Figure 13. Others Product Picture
Figure 14. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Preclinical and IND-enabling Manufacturing Product Picture
Figure 16. Phase I Clinical Manufacturing Product Picture
Figure 17. Phase II Clinical Manufacturing Product Picture
Figure 18. Phase III Clinical Manufacturing Product Picture
Figure 19. Others Product Picture
Figure 20. Global Biopharmaceutical Contract Manufacturing (BCMO) Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 21. Bio-Pharmaceutical Companies
Figure 22. Pharmaceutical Companies
Figure 23. Drug Discovery Companies
Figure 24. Others
Figure 25. Biopharmaceutical Contract Manufacturing (BCMO) Report Years Considered
Figure 26. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 27. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 28. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 29. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue-Based Market Share by Region (2021-2032)
Figure 30. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue-Based Market Share Ranking (2025)
Figure 31. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 32. Monoclonal and Multispecific Antibodies Revenue-Based Market Share by Player in 2025
Figure 33. Antibody-Drug Conjugates (ADCs) Revenue-Based Market Share by Player in 2025
Figure 34. Vaccines Revenue-Based Market Share by Player in 2025
Figure 35. Cell Therapy Products Revenue-Based Market Share by Player in 2025
Figure 36. Gene Therapy and Viral Vector Products Revenue-Based Market Share by Player in 2025
Figure 37. Nucleic Acid Therapeutics Revenue-Based Market Share by Player in 2025
Figure 38. Others Revenue-Based Market Share by Player in 2025
Figure 39. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue-Based Market Share by Type (2021-2032)
Figure 40. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue-Based Market Share by Manufacturing Service Type (2021-2032)
Figure 41. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue-Based Market Share by Development and Commercialization Stage (2021-2032)
Figure 42. Global Biopharmaceutical Contract Manufacturing (BCMO) Revenue-Based Market Share by Application (2021-2032)
Figure 43. North America Biopharmaceutical Contract Manufacturing (BCMO) Revenue YoY (US$ Million), 2021-2032
Figure 44. North America Top 5 Players Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) in 2025
Figure 45. North America Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) by Application (2021-2032)
Figure 46. US Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 47. Canada Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 48. Mexico Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 49. Europe Biopharmaceutical Contract Manufacturing (BCMO) Revenue YoY (US$ Million), 2021-2032
Figure 50. Europe Top 5 Players Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) in 2025
Figure 51. Europe Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) by Application (2021-2032)
Figure 52. Germany Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 53. France Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 54. U.K. Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 55. Italy Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 56. Russia Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 57. Asia-Pacific Biopharmaceutical Contract Manufacturing (BCMO) Revenue YoY (US$ Million), 2021-2032
Figure 58. Asia-Pacific Top 8 Players Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) in 2025
Figure 59. Asia-Pacific Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) by Application (2021-2032)
Figure 60. Indonesia Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 61. Japan Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 62. South Korea Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 63. Australia Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 64. India Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 65. Indonesia Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 66. Vietnam Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 67. Malaysia Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 68. Philippines Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 69. Singapore Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 70. Central and South America Biopharmaceutical Contract Manufacturing (BCMO) Revenue YoY (US$ Million), 2021-2032
Figure 71. Central and South America Top 5 Players Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) in 2025
Figure 72. Central and South America Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) by Application (2021-2032)
Figure 73. Brazil Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 74. Argentina Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 75. Middle East and Africa Biopharmaceutical Contract Manufacturing (BCMO) Revenue YoY (US$ Million), 2021-2032
Figure 76. Middle East and Africa Top 5 Players Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) in 2025
Figure 77. Middle East and Africa Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million) by Application (2021-2032)
Figure 78. GCC Countries Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 79. Israel Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 80. Egypt Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 81. South Africa Biopharmaceutical Contract Manufacturing (BCMO) Revenue (US$ Million), 2021-2032
Figure 82. Biopharmaceutical Contract Manufacturing (BCMO) Value Chain Mapping
Figure 83. Channels of Distribution (Direct Vs Distribution)
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(biopharmaceutical)の最新刊レポート



関連レポート(キーワード「バイオ医薬品」)


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/11/20 10:25

160.51 円

176.53 円

212.83 円

ページTOPに戻る